Physician profile
Pablo M Pella
NPI 1245347004
$123,718.96
in general payments reported to CMS, 2019-2025
29 companies · $16K in 2025
The $16K reported for 2025 was more than what 95% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $9,705 · 2021: $8,740 · 2022: $20K · 2023: $17K · 2024: $17K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $13K · Travel and Lodging: $2,053 · Consulting Fee: $1,620 · Education: $21.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,340.00 |
| Food and Beverage | $13,120.51 |
| Travel and Lodging | $2,053.40 |
| Consulting Fee | $1,620.00 |
| Education | $21.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $100,567.62 | 2019-2025 | Biktarvy, Sunlenca, Descovy |
| Viiv Healthcare Company | $13,174.29 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $1,836.39 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Abbvie INC. | $1,724.46 | 2019-2025 | |
| Theratechnologies INC. | $1,646.26 | 2019-2025 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $1,200.24 | 2019-2023 | Symtuza |
| Insmed, INC. | $810.93 | 2019-2025 | Arikayce |
| Janssen Products, Lp | $393.01 | 2019-2022 | |
| Melinta Therapeutics, LLC | $352.43 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Shionogi INC | $298.77 | 2021-2025 | Fetroja |
| Emd Serono, INC. | $254.95 | 2019-2025 | Serostim |
| Allergan, INC. | $253.89 | 2019 | |
| Napo Pharmaceuticals INC | $224.12 | 2019-2025 | Mytesi |
| Paratek Pharmaceuticals, INC. | $199.52 | 2023-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $176.90 | 2023-2025 | Xerava, Zevtera, Xacduro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $124.99 | 2019 | |
| Janssen Scientific Affairs, LLC | $93.65 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.34 | 2025 | Cuvitru |
| Aimmune Therapeutics, INC. | $55.32 | 2024-2025 | Vowst |
| Teva Pharmaceuticals USA, INC. | $47.84 | 2022-2023 | Uzedy |
| Tetraphase Pharmaceuticals, INC. | $42.09 | 2019-2025 | |
| Pfizer INC. | $37.33 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.50 | 2023 | |
| Hikma Pharmaceuticals USA | $16.98 | 2024 | Kloxxado |
| Rockwell Medical, INC. | $16.45 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $15.36 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.60 | 2022 | |
| Vyera Pharmaceuticals, LLC | $11.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Pella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.